Ocular Hypertension Clinical Trial
Official title:
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension.
NCT number | NCT00159653 |
Other study ID # | A6641027 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | July 2005 |
Est. completion date | June 2007 |
Verified date | October 2012 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Status | Completed |
Enrollment | 500 |
Est. completion date | June 2007 |
Est. primary completion date | June 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening Exclusion Criteria: - Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma. - History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening |
Country | Name | City | State |
---|---|---|---|
Canada | Pfizer Investigational Site | Barrie | Ontario |
Canada | Pfizer Investigational Site | Bridgewater | Nova Scotia |
Canada | Pfizer Investigational Site | Calgary | Alberta |
Canada | Pfizer Investigational Site | Markham | Ontario |
Canada | Pfizer Investigational Site | Mississauga | Ontario |
Canada | Pfizer Investigational Site | Moncton | New Brunswick |
Canada | Pfizer Investigational Site | Montreal | Quebec |
Canada | Pfizer Investigational Site | Montreal | Quebec |
Canada | Pfizer Investigational Site | Nanaimo | British Columbia |
Canada | Pfizer Investigational Site | Oakville | Ontario |
Canada | Pfizer Investigational Site | Saint John | New Brunswick |
Canada | Pfizer Investigational Site | Saint John | New Brunswick |
Canada | Pfizer Investigational Site | Saskatoon | Saskatchewan |
Canada | Pfizer Investigational Site | Saskatoon | Saskatchewan |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
United States | Pfizer Investigational Site | Amarillo | Texas |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Bethpage | New York |
United States | Pfizer Investigational Site | Cape Coral | Florida |
United States | Pfizer Investigational Site | Charlotte | North Carolina |
United States | Pfizer Investigational Site | Charlotte | North Carolina |
United States | Pfizer Investigational Site | Cranberry Township | Pennsylvania |
United States | Pfizer Investigational Site | Danbury | Connecticut |
United States | Pfizer Investigational Site | High Point | North Carolina |
United States | Pfizer Investigational Site | Homewood | Illinois |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Lakeland | Florida |
United States | Pfizer Investigational Site | Lincoln | Nebraska |
United States | Pfizer Investigational Site | Louisville | Kentucky |
United States | Pfizer Investigational Site | Matthews | North Carolina |
United States | Pfizer Investigational Site | Memphis | Tennessee |
United States | Pfizer Investigational Site | Morrow | Georgia |
United States | Pfizer Investigational Site | Mount Pleasant | South Carolina |
United States | Pfizer Investigational Site | Mount Pleasant | South Carolina |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Newark | New Jersey |
United States | Pfizer Investigational Site | North Charleston | South Carolina |
United States | Pfizer Investigational Site | North Dartmouth | Massachusetts |
United States | Pfizer Investigational Site | Omaha | Nebraska |
United States | Pfizer Investigational Site | Ormond Beach | Florida |
United States | Pfizer Investigational Site | Overland Park | Kansas |
United States | Pfizer Investigational Site | Phoenix | Arizona |
United States | Pfizer Investigational Site | Pittsburgh | Pennsylvania |
United States | Pfizer Investigational Site | Poway | California |
United States | Pfizer Investigational Site | Redding | California |
United States | Pfizer Investigational Site | Redding | California |
United States | Pfizer Investigational Site | Saint Joseph | Michigan |
United States | Pfizer Investigational Site | Shreveport | Louisiana |
United States | Pfizer Investigational Site | Tampa | Florida |
United States | Pfizer Investigational Site | Tulsa | Oklahoma |
United States | Pfizer Investigational Site | Wilmington | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The mean IOP measurements obtained in the study eye at each time point |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01340014 -
Patient Preference Comparison of AZARGA Versus COSOPT
|
Phase 4 | |
Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 |